KemPharm Inc (KMPH) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 14 from a previous price target of $22 . RBC Capital Mkts advised their investors in a research report released on May 6, 2016.
KemPharm Inc closed down -8.76 points or -55.90% at $6.91 with 21,96,879 shares getting traded on Friday. Post opening the session at $8.57, the shares hit an intraday low of $6.88 and an intraday high of $8.7495 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Mar 30, 2016, Travis C Mickle (CEO) purchased 2,450 shares at $14.54 per share price. According to the SEC, on Mar 30, 2016, Christal M M Mickle (VP Prod Dev) purchased 2,450 shares at $14.54 per share price. On May 12, 2015, Gordon K Johnson (CFO) purchased 2,000 shares at $11.00 per share price, according to the Form-4 filing with the securities and exchange commission.
KemPharm Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company through its Ligand Activated Therapy (LAT) platform technology creates NME prodrug product candidates. The Company’s NME prodrug product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD) and KP303 for the treatment of central nervous system (CNS) disorders. The Company’s product’s KP201/APAP is in clinical trial stage and KP511/ER KP415 KP606/ER and KP303 are in preclinical trail stage.